Search results
Results from the WOW.Com Content Network
About 50% of CIN 2 cases will regress within two years without treatment. [citation needed] Progression to cervical carcinoma in situ (CIS) occurs in approximately 11% of CIN 1 and 22% of CIN 2 cases. Progression to invasive cancer occurs in approximately 1% of CIN 1, 5% of CIN 2, and at least 12% of CIN 3 cases.
Cervical squamous intraepithelial lesion (SIL), previously called cervical intraepithelial neoplasia (CIN), is a form of dysplasia that can progress to cervical cancer. The term carcinoma in situ may be used interchangeably with high-grade SIL. [8] Ductal carcinoma in situ of the breast is the most common precancer in women. Bowen's disease is ...
Cervical cancer begins when the cells that line the cervix become abnormal and grow in a pattern that is atypical for non-cancerous cells. [14] Cervical cancer is typically first identified with an abnormal pap smear. [14] The final diagnosis of cervical cancer, including the stage of the cancer, is confirmed with additional testing. [12]
Results from a phase 3 clinical trial show promise for a new standard of care for treating people with advanced cervical cancer. The new treatment includes a combination of induction chemotherapy ...
Sometimes, the term "precancer" is also used for carcinoma in situ, which is a noninvasive cancer that has not grown and spread to nearby tissue, unlike the invasive stage. As with other precancerous conditions, not all carcinoma in situ will become an invasive disease but is at risk of doing so.
Treatment is usually straightforward. High-grade dysplasia represents a more advanced progression towards malignant transformation. Carcinoma in situ, meaning "cancer in place", represents the transformation of a neoplastic lesion to one in which cells undergo essentially no maturation, thus may be considered cancer-like. In this state ...
High-grade squamous intraepithelial lesion (HSIL or HGSIL) indicates moderate or severe cervical intraepithelial neoplasia or carcinoma in situ. It is usually diagnosed following a Pap test. In some cases these lesions can lead to invasive cervical cancer, if not followed appropriately. [citation needed] HSIL does not mean that cancer is present.
The Australian Cervical Cancer Foundation (ACCF), founded in 2008, promotes 'women's health by eliminating cervical cancer and enabling treatment for women with cervical cancer and related health issues, in Australia and in developing countries.' [168] Ian Frazer, one of the developers of the Gardasil cervical cancer vaccine, is the scientific ...